SIGLEC1 and cancer: Animal studies using transgenic mice, which deplete CD169-expressing cells by diphtheria toxin, have demonstrated that LSMs can engulf dead cancer cells and activate cancer antigen-specific cytotoxic T lymphocytes through cross-presentation [8].